PLX
Protalix BioTherapeutics, Inc. AMEX Listed May 15, 1998$2.71
+0.19%
vs $2.70
Mkt Cap $217.9M
52w Low $1.60
69.5% of range
52w High $3.19
50d MA $2.46
200d MA $2.28
P/E (TTM)
11.5x
EV/EBITDA
6.9x
P/B
4.4x
Debt/Equity
0.2x
ROE
-13.7%
P/FCF
-15.6x
RSI (14)
56.70
ATR (14)
$0.09
Beta
-0.09
50d MA
$2.46
200d MA
$2.28
Avg Volume
787.1K
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
2 University Plaza · Hackensack, NJ 07601 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | BMO | -0.01 | 0.05 | +600.0% | 2.43 | +2.5% | +7.8% | -9.9% | -5.9% | +3.2% | +2.2% | — |
| May 13, 2026 | BMO | -0.01 | 0.22 | +2300.0% | 1.91 | +3.1% | +1.0% | +3.6% | -1.0% | -3.5% | -0.5% | — |
| Mar 18, 2026 | BMO | 0.01 | -0.07 | -800.0% | 2.21 | +0.5% | +0.9% | -4.0% | -0.5% | -2.8% | +4.3% | — |
| Nov 13, 2025 | BMO | 0.06 | 0.03 | -50.0% | 1.93 | -11.4% | -3.6% | +1.6% | -0.5% | -5.9% | -1.7% | — |
| Aug 14, 2025 | BMO | 0.03 | 0.00 | -93.3% | 1.52 | +0.0% | -2.6% | +4.1% | -0.6% | +2.6% | +0.6% | — |
| May 9, 2025 | BMO | 0.08 | -0.05 | -162.5% | 1.72 | +0.6% | -15.1% | +13.7% | +0.6% | +0.0% | +0.0% | — |
| Mar 17, 2025 | BMO | 0.07 | 0.09 | +28.6% | 2.45 | +1.6% | -4.1% | -4.3% | +4.9% | +5.5% | +4.4% | — |
| Nov 14, 2024 | BMO | 0.06 | 0.03 | -50.0% | 1.41 | -2.1% | -0.7% | +18.6% | -1.8% | +3.7% | -1.8% | — |
| Aug 14, 2024 | BMO | -0.01 | -0.03 | -249.7% | 0.93 | +0.0% | +2.2% | +2.2% | -1.2% | -0.9% | +2.0% | — |
| May 10, 2024 | BMO | -0.02 | -0.06 | -200.0% | 1.10 | +2.7% | +3.6% | +1.8% | -2.6% | +3.5% | -2.6% | — |
| Mar 14, 2024 | BMO | -0.03 | -0.07 | -133.3% | 1.37 | +1.5% | -2.9% | -4.5% | +2.4% | +3.1% | -1.5% | — |
| Nov 6, 2023 | BMO | -0.07 | -0.04 | +42.9% | 1.51 | +1.3% | -0.7% | -8.7% | +1.5% | -3.6% | +0.7% | — |
| Aug 7, 2023 | BMO | 0.03 | 0.21 | +624.8% | 1.90 | -4.2% | +1.1% | -4.7% | +3.3% | +1.6% | +3.6% | — |
| May 4, 2023 | AMC | — | -0.05 | — | 3.36 | +4.2% | -2.7% | -7.0% | -3.9% | +0.7% | -13.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.21 | $2.22 | +0.5% | +0.9% | -4.0% | -0.5% | -2.8% | +4.3% |
| Nov 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.74 | $1.71 | -1.7% | +0.6% | +0.0% | +2.3% | +2.2% | -2.7% |
| Feb 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.43 | $2.36 | -2.9% | -0.4% | +4.1% | +6.0% | +0.7% | -1.1% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.35 | $1.37 | +1.5% | +1.5% | +2.9% | -1.4% | +0.7% | -0.7% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.49 | $1.48 | -0.7% | +12.1% | -3.0% | +4.3% | +9.5% | -18.4% |
| Jun 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.59 | $3.96 | +10.3% | +7.2% | +0.0% | -1.6% | -3.7% | -2.7% |
| Apr 17 | Rodman & Renshaw | Maintains | Buy → Buy | — | $10.50 | $11.00 | +4.8% | +0.0% | -1.0% | +0.0% | -3.8% | +2.0% |
| Sep 6 | Jefferies | Maintains | Buy → Buy | — | $6.00 | $6.09 | +1.5% | +3.4% | -1.6% | -2.7% | +4.1% | +1.9% |
| Apr 4 | Rodman & Renshaw | Maintains | Buy → Buy | — | $8.40 | $8.90 | +6.0% | +2.7% | -2.7% | +5.9% | -0.0% | +1.1% |
| Apr 23 | Jefferies | Maintains | Buy → Buy | — | $20.80 | $21.30 | +2.4% | +6.7% | +0.5% | -4.9% | +0.9% | +2.8% |
| May 13 | JP Morgan | Maintains | Overweight → Overweight | — | $37.90 | $39.10 | +3.2% | +2.9% | -2.3% | -1.0% | +1.3% | +1.6% |
| May 12 | Jefferies | Maintains | Hold → Hold | — | $38.50 | $38.80 | +0.8% | -1.6% | +2.9% | -2.3% | -1.0% | +1.3% |
| Jan 23 | RF Lafferty | Maintains | Buy → Buy | — | $46.00 | $46.00 | +0.0% | -1.7% | -1.1% | -4.7% | +1.4% | -3.2% |
| Oct 21 | JP Morgan | Maintains | Overweight → Overweight | — | $44.30 | $46.60 | +5.2% | -1.1% | +2.5% | +0.7% | +0.0% | -0.7% |
| Nov 9 | Jefferies | Maintains | Hold → Hold | — | $48.60 | $48.00 | -1.2% | +0.8% | -0.4% | +8.8% | +0.4% | -0.6% |
| Jul 16 | Aegis Capital | Maintains | Hold → Hold | — | $58.00 | $57.00 | -1.7% | -1.4% | -0.9% | -1.9% | +2.5% | +0.4% |
| Jun 25 | Wells Fargo | Downgrade | Outperform → Perform | — | $61.90 | $60.40 | -2.4% | -5.8% | -4.3% | +1.1% | -0.2% | +1.8% |
No insider trades available.
8-K
Protalix BioTherapeutics, Inc. -- 8-K Filing
Aug 12
8-K · 7.01
! Medium
Protalix BioTherapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
May 21
8-K
Protalix BioTherapeutics, Inc. -- 8-K Filing
May 13
8-K
Unknown — 8-K Filing
PLX reported FY2025 results and clinical updates for its rare disease therapeutics, indicating operational progress that investors should monitor for pipeline advancement and cash runway sustainability in a capital-intensive biotech sector.
Mar 18
8-K
Protalix BioTherapeutics, Inc. -- 8-K Filing
Protalix announced a four-week dosing regimen for Elfabrio outside the US, which could potentially expand treatment convenience and market adoption for its Fabry disease therapy internationally.
Mar 9
8-K · 7.01
! Medium
Protalix BioTherapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Protalix BioTherapeutics furnished a corporate presentation for investor disclosure, providing updated company information through a Form 8-K filing.
Feb 11
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Blackrock, Inc. | 4,046,650 | $9M | New | Jun 2026 |
| 2 | Opaleye Management Inc. | 2,478,176 | $4M | Reduced | Dec 2025 |
| 3 | Renaissance Technologies Llc | 1,096,000 | $3M | Reduced | Jun 2026 |
| 4 | Northern Trust Corp | 885,448 | $2M | Added | Mar 2026 |
| 5 | Citadel Advisors Llc | 668,454 | $2M | New | Jun 2026 |
| 6 | Vanguard Portfolio Management Llc | 510,639 | $1M | Added | Jun 2026 |
| 7 | Stratos Wealth Partners, Ltd. | 500,000 | $1M | — | Mar 2026 |
| 8 | Strs Ohio | 296,100 | $690K | New | Jun 2026 |
| 9 | Ubs Group Ag | 265,535 | $576K | Added | Mar 2026 |
| 10 | Jane Street Group, Llc | 289,917 | $522K | New | Dec 2025 |
| 11 | Bank Of New York Mellon Corp | 219,307 | $476K | Added | Mar 2026 |
| 12 | Morgan Stanley | 263,974 | $475K | Added | Dec 2025 |
| 13 | Millennium Management Llc | 171,535 | $400K | New | Jun 2026 |
| 14 | Aqr Capital Management Llc | 167,826 | $391K | Added | Jun 2026 |
| 15 | Evergreen Capital Management Llc | 171,338 | $372K | — | Mar 2026 |
| 16 | Commonwealth Equity Services, Llc | 171,772 | $309K | — | Dec 2025 |
| 17 | Nuveen, Llc | 90,188 | $210K | — | Jun 2026 |
| 18 | Bank Of America Corp /de/ | 79,079 | $172K | Added | Mar 2026 |
| 19 | State Of Wyoming | 59,179 | $138K | New | Jun 2026 |
| 20 | Rhumbline Advisers | 46,224 | $108K | New | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$217.9M
Enterprise Value
$181.1M
P/E (TTM)
11.48x
Forward P/E
12.58x
PEG Ratio
0.07x
P/B
4.41x
P/S
2.64x
P/FCF
-15.56x
EV/EBITDA
6.89x
Shares Out
78.5M
Financials (TTM)
Revenue
$80.6M
Net Income
$18.9M
EBITDA
$26.3M
Free Cash Flow
-$13.6M
Op Cash Flow
-$12.0M
EPS Basic
$-0.08
EPS Diluted
$0.23
EPS Forward
$0.21
Gross Margin
69.2%
Op Margin
28.9%
Net Margin
23.5%
Balance Sheet
Total Assets
$82.3M
Total Liab.
$34.1M
Total Equity
$48.2M
Cash
$31.0M
LT Debt
$0
Book Value/Sh
$0.61
Debt/Equity
0.17x
Current Ratio
2.51
Quick Ratio
1.54
Returns & Growth
ROE
-13.7%
ROA
-8.0%
ROIC
-9.6%
Rev Growth YoY
-1.2%
EPS Growth YoY
-308.2%
Price Returns
2W
+4.2%
1M
+15.4%
3M
+21.6%
6M
+22.2%
12M
+45.2%
Technicals
52W High
$3.19
52W Low
$1.60
50d MA
$2.46
200d MA
$2.28
RSI (14)
56.70
ATR (14)
$0.09
Beta
-0.09
Avg Volume
787K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 26, 2026 8:04pm
· Source: financialmodelingprep.com